耐药结核病患者中的利奈唑胺毒性:一项前瞻性队列研究
本前瞻性观察性队列研究在南非耐利福平结核病患者中描述利奈唑胺毒性的发生率和决定因素,并确定毒性药物暴露阈值。151例参与者中63%为HIV阳性,中位随访86周;32例(21%)因毒性永久停用利奈唑胺,21例(14%)发生3级或4级不良事件;利奈唑胺谷浓度2.5 mg/L或以上与治疗中出现贫血相关(校正OR 2.9;95%CI 1.3-6.8)。
要点
- 利奈唑胺因毒性永久停药常见,151例中32例(21%)停用。
- 3级或4级利奈唑胺相关不良事件发生于21例(14%)。
- 谷浓度2.5 mg/L或以上与贫血相关(校正OR 2.9;95%CI 1.3-6.8)。
核心结论
- 利奈唑胺永久停药常见,但含利奈唑胺治疗与毒性指标平均改善相关。
- HIV合并感染与利奈唑胺毒性无独立关联。
- 利奈唑胺谷浓度2.5 mg/L应作为治疗药物监测的目标进行评估。
研究设计与样本
- 在南非开展的观察性队列研究,纳入耐利福平结核病患者。
- 共151例参与者,63%为HIV阳性,中位随访86周。
- 利奈唑胺暴露量由群体药代动力学模型估算,采用混合效应模型分析毒性结局。
主要发现
- 32例(21%)参与者因毒性永久停用利奈唑胺。
- 21例(14%)参与者发生3级或4级利奈唑胺相关不良事件。
- 平均血红蛋白浓度随治疗时间增加(每周0.03 g/dL;95%CI 0.02-0.03)。
- 利奈唑胺谷浓度、男性和年龄(而非HIV阳性)与血红蛋白下降超过2 g/dL独立相关。
- 线粒体DNA SNPs 2706A>G和3010G>A与利奈唑胺毒性无关。
关键数值与推荐
- 利奈唑胺谷浓度2.5 mg/L或以上时模型性能最优,可描述血红蛋白变化和治疗中出现贫血(校正OR 2.9;95%CI 1.3-6.8)。
临床怎么用
- 利奈唑胺谷浓度2.5 mg/L应作为治疗药物监测的目标进行评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid is recommended for treating drug-resistant TB. Adverse events are a concern to prescribers but have not been systematically studied at the standard dose, and the relationship between linezolid exposure and clinical toxicity is not completely elucidated. PATIENTS AND METHODS: We conducted an observational cohort study to describe the incidence and determinants of linezolid toxicity, and to determine a drug exposure threshold for toxicity, among patients with rifampicin-resistant TB in South Africa. Linezolid exposures were estimated from a population pharmacokinetic model. Mixed-effects modelling was used to analyse toxicity outcomes. RESULTS: One hundred and fifty-one participants, 63% HIV positive, were enrolled and followed for a median of 86 weeks. Linezolid was permanently discontinued for toxicity in 32 (21%) participants. Grade 3 or 4 linezolid-associated adverse events occurred in 21 (14%) participants. Mean haemoglobin concentrations increased with time on treatment (0.03 g/dL per week; 95% CI 0.02-0.03). Linezolid trough concentration, male sex and age (but not HIV positivity) were independently associated with a decrease in haemoglobin >2 g/dL. Trough linezolid concentration of 2.5 mg/L or higher resulted in optimal model performance to describe changing haemoglobin and treatment-emergent anaemia (adjusted OR 2.9; 95% CI 1.3-6.8). SNPs 2706A > G and 3010G > A in mitochondrial DNA were not associated with linezolid toxicity. CONCLUSIONS: Permanent discontinuation of linezolid was common, but linezolid-containing therapy was associated with average improvement in toxicity measures. HIV co-infection was not independently associated with linezolid toxicity. Linezolid trough concentration of 2.5 mg/L should be evaluated as a target for therapeutic drug monitoring.
引用
- Wasserman S, Brust JCM, Abdelwahab MT, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022. PMID: 35134182. doi:10.1093/jac/dkac019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。